Phillip Chan
Chief Executive Officer @CytoSorbents Corporation
Signup · Get unlimited contacts
WORK HISTORY
Chief Executive Officer @CytoSorbents Corporation
CytoSorbents (NASDAQ: CTSO) is a publicly-traded, critical care immunotherapy company using blood purification to control cytokine storm and hyperinflammation in deadly diseases such as sepsis, COVID-19 (under U.S. FDA Emergency Use Authorization), burns, trauma, ARDS, and cytokine release syndrome. The Company\'s flagship product, CytoSorb®, is a highly efficient cytokine adsorber approved in the European Union to fight cytokine storm in critical illnesses that could otherwise cause massive inflammation and organ failure, the leading cause of death in the ICU. CytoSorb is also being used during open heart surgery to remove free hemoglobin and other inflammatory mediators that can cause post-op inflammation and organ damage. CytoSorb is also E.U. approved to remove the anti-thrombotic agents, ticagrelor (Brilinta) and rivaroxaban (Xarelto) during on-pump cardiothoracic surgery. In the U.S. and Canada, the pivotal STAR-T RCT is expected to complete in 2023 and support FDA and Health Canada marketing approval of DrugSorb-ATR for Brilinta removal under FDA Breakthrough Designation. With E.U. regulatory approval for CytoSorb, ISO 13485 manufacturing in NJ, reimbursement and a direct sales force in Germany, distribution in 75 countries worldwide, strategic partnerships with Fresenius Medical Care, B Braun, Biocon, Terumo Cardiovascular, and a hardware agreement with Nikkiso, and 2022 total revenue of $34.7M, CytoSorbents is an exciting emerging growth company that is helping to save lives and to reduce the exorbitant costs of ICU care. The technology has received ~$48M in support from DARPA, NIH, US Army, Air Force, HHS and others. This adds to a significant internal R&D effort that has resulted in promising development stage products such as HemoDefend-RBC (pRBC) and HemoDefend-BGA (plasma) for blood transfusions, K+ontrol (hyperkalemia), CytoSorb XL, DrugSorb (drug overdose), and ContrastSorb (contrast-induced nephropathy).
EDUCATION
Cornell University
BS, Cell and Molecular Biology
Harvard Medical School
Internal Medicine Residency - Beth Israel Deaconess Medical Center
Yale School of Medicine
MD/PhD, Medicine and Genetics
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.